Abstract
Cancer-associated cachexia, marked by progressive muscle atrophy and metabolic dysfunction, poses a significant therapeutic challenge. To address carnosol's metabolic instability, we rationally designed 35 derivatives by replacing its oxidation-prone 11,12-phenolic groups with oxazole rings or aryl moieties. SAR-guided optimization identified 10 as the lead compound. In C26 tumor-conditioned models, 10 attenuated myotube atrophy (67.08 % reversal) and adipocyte lipolysis. In C26 tumor-bearing mice, 10 alleviated cachexia-related weight loss without altering tumor progression. Pharmacokinetic studies revealed enhanced stability: a half-life of 11.1 h and an AUC0-t of 8369 ng/mL. These results position 10 as a promising therapeutic candidate for cancer cachexia, while offering a strategic framework for rational optimization of natural product.
| Original language | English |
|---|---|
| Article number | 130420 |
| Journal | Bioorganic and Medicinal Chemistry Letters |
| Volume | 130 |
| DOIs | |
| State | Published - 1 Jan 2026 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Cancer-associated Cachexia
- Carnosol
- Structure–activity relationship
Fingerprint
Dive into the research topics of 'Synthesis, structure–activity relationships of carnosol derivatives for cancer-associated cachexia'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver